Lisata Therapeutics Receives $2.2 Million of Non-Dilutive Capital Through New Jersey Technology Business Tax Certificate Transfer Program
BASKING RIDGE, N.J., April 20, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
Year: 2023
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading…
Wave Life Sciences Announces Nucleic Acids Research Publication Highlighting Potential Best-in-Class siRNAs Designed with Wave Platform Chemistry
Published preclinical data demonstrate unprecedented Ago2 loading following administration of single subcutaneous siRNA dose, leading…
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Catalyst Pharmaceuticals Announces Third-Party Abstracts on FYCOMPA® (Perampanel) to be Presented at the Upcoming American Academy of Neurology 2023 Annual Meeting
CORAL GABLES, Fla., April 20, 2023 (GLOBE NEWSWIRE) — Catalyst Pharmaceuticals, Inc. (“Catalyst”) (Nasdaq: CPRX),…
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
Ocugen to Present at Association for Research in Vision and Ophthalmology 2023 Annual Meeting
MALVERN, Pa., April 20, 2023 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ:…
ProQR Announces Upcoming Investor Conferences in April and May
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq:…
ProQR Announces Upcoming Investor Conferences in April and May
LEIDEN, Netherlands & CAMBRIDGE, Mass., April 20, 2023 (GLOBE NEWSWIRE) — ProQR Therapeutics NV. (Nasdaq:…
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
BetterLife To Present at the 2023 Bloom Burton & Co. Healthcare Investor Conference
VANCOUVER, British Columbia, April 20, 2023 (GLOBE NEWSWIRE) — BetterLife Pharma Inc. (“BetterLife” or the…
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
Collegium to Report First Quarter 2023 Financial Results on May 4, 2023
STOUGHTON, Mass., April 20, 2023 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL), a leading, diversified…
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
BOSTON, April 20, 2023 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted…
Ikena Oncology to Participate in the Stifel 2023 Virtual Targeted Oncology Days
BOSTON, April 20, 2023 (GLOBE NEWSWIRE) — Ikena Oncology, Inc. (Nasdaq: IKNA, “Ikena”), a targeted…
PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA
Fourth major clinical trial to select PharmAla Biotech as supplier in Australia VANCOUVER, British Columbia,…
PharmAla Biotech to supply Clinical Psychedelic Lab at Monash University Clinical Trial with LaNeo MDMA
Fourth major clinical trial to select PharmAla Biotech as supplier in Australia VANCOUVER, British Columbia,…
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
– Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid…
Viridian Therapeutics Announces Presentations at the 2023 Annual Meeting of the Association for Research in Vision and Ophthalmology
– Presentations to cover updated clinical and preclinical data on pipeline candidates in Company’s thyroid…
Locanabio Announces First Presentation of Data from its Next Generation Vectorized snRNA Exon-Skipping Platform Highlighting its Investigational LBIO-115 Program for the Treatment of Duchenne Muscular Dystrophy (DMD)
Preclinical data from LBIO-115 exon 51 program demonstrate superior levels of exon-skipping that result in…